Temporal and spatial patterns of osteoblast activation following implantation of beta-TCP particles into bone.
Temporal and spatial patterns of osteoblast activation around beta-TCP particles implanted into bone were analyzed by in situ hybridization with digoxygenin-labeled procollagen alpha 1(I) RNA probes. beta-TCP particles (150-300 microns in diameter) were implanted into rat tibiae, and specimens were collected 3, 5, 7, 14, and 28 days after operation. Activated osteoblasts displayed intense procollagen alpha 1(I) RNA specific labeling. At day 3, osteoblasts lining pre-existing trabeculae in places showed a specific signal. Additionally, scattered activated cells compatible with preosteoblasts also were observed in the vicinity of the trabeculae among red blood cells that filled the space between beta-TCP particles. Osteoblast activation on the surface of beta-TCP rarely was observed. At days 5 and 7, osteoblast activation and bone formation advanced centripetally. At the forefront of bone formation positive cells were scattered in the blood cell clots, and some of the positive cells colonized forming new bone matrix. Formation of new bone did not always begin at the surface of beta-TCP. At day 14, most of the beta-TCP particles were tightly associated with newly formed bone, and the number of positive osteoblasts was reduced. At day 28, absorption of the newly formed bone and the beta-TCP by multinuclear cells was sporadically demonstrated. Such cells often were accompanied by active osteoblasts, suggesting early bone remodeling. In conclusion, in situ hybridization with procollagen alpha 1(I) was employed to demonstrate precisely the mode of recruitment of bone cell precursors. beta-TCP does not positively guide collagen I expressing bone cells along its surface. It has no apparent effects on bone regeneration.
Neo
M
M
Institute of Pathology, University Hospital Benjamin Franklin, Free University, Berlin, Germany.
Herbst
H
H
Voigt
C F
CF
Gross
U M
UM
D000818:Animals; D001672:Biocompatible Materials / Q000009:adverse effects; D018786:Bone Substitutes; D002130:Calcium Phosphates / Q000009:adverse effects; D003094:Collagen / Q000378:metabolism*; D017403:In Situ Hybridization; D008297:Male; D010006:Osteoblasts / Q000378:metabolism* / Q000473:pathology*; D051381:Rats; D017208:Rats, Wistar
D001672:Biocompatible Materials; D018786:Bone Substitutes; D002130:Calcium Phosphates; C485817:beta-tricalcium phosphate; D003094:Collagen; C018392:tricalcium phosphate